πŸ‡°πŸ‡·South KoreaΒ·PolicyΒ·16 Nov 2026Β·via Pr Newswire Apac

    WIRobotics and Ottobock Join Forces to Expand Access to Wearable Robots Across North America

    South Korea's WIRobotics, a global robotics company, has signed a distribution and sales agreement with Germany-based Otto Bock HealthCare LP to expand the reach of its WIM S wearable mobility robot across North America. The agreement, finalized on October 15, establishes Ottobock as a distribution partner in the United States and Canada.

    WIRobotics USA Inc., the U.S. subsidiary of South Korean robotics firm WIRobotics, entered a distribution and sales agreement with Otto Bock HealthCare LP on October 15. Under this arrangement, WIRobotics USA will supply its WIM S wearable mobility robot, while Ottobock will manage distribution in the United States and Canada.

    The partnership leverages Ottobock's more than 100 years of experience in human mobility and its established distribution, clinical care, and service networks across North America. WIRobotics, co-led by Younbaek Lee and Yongjae Kim, sees this as a major step in its global expansion, having identified the United States and Canada as key strategic markets.

    Initial sales through the partnership will focus on the United States. Consumers there can purchase WIM S online via Ottobock's direct-to-consumer platform and WIRobotics USA's online store. To allow for direct interaction with the device, opportunities to try the robot will also be available at select orthotic and prosthetic (O&P) clinics.

    The companies plan to use customer feedback from this initial U.S. rollout to decide on offering hands-on experiences at more locations. They will also consider extending sales through the partnership to Canada after this initial phase. WIRobotics USA, under General Manager Jacob Kim, will support local training and service operations.

    WIRobotics has been accelerating its international business, with its WIM series already sold beyond South Korea to markets including Europe, China, and Japan, surpassing 4,000 units in cumulative sales. The company raised KRW 95 billion (approximately USD 68 million) in Series B funding in May 2026 to help accelerate this global expansion.

    Both companies also see potential for future collaboration on WIRobotics' WIM Medi, a robot currently under development for medical use. Any expansion into U.S. and Canadian medical and rehabilitation channels would be subject to applicable regulatory authorization and a separate agreement, indicating a longer-term strategic alignment beyond the immediate consumer product.

    Share this article

    Original reporting by Pr Newswire ApacWe don't republish, read the full story β†’

    Related reading

    6 stories